Journal of Clinical Immunology

, Volume 38, Issue 5, pp 556–557 | Cite as

Renal Disease in Chronic Granulomatous Disease: Data from the USIDNET Registry

  • Keith A. SaccoEmail author
  • Elizabeth Garabedian
  • Kathleen E. Sullivan
  • The USIDNET Consortium
  • Avni Y. Joshi
Letter to Editor

To the editor:

Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by mutations in genes encoding NADPH oxidase complex protein subunits, which leads to skin and soft tissue infection, pneumonia, abscesses, and granulomatous inflammation all of which could be life-threatening [1]. Prophylactic antimicrobials are the mainstay of treatment for CGD. Some of these antimicrobials are nephrotoxic and may lead to end-stage renal disease (ESRD) [2]. The aim of our study was to assess the prevalence of ESRD in CGD patients using the USIDNET registry.

We queried the USIDNET database on 28 March 2017 requesting demographic data on CGD patients, number of CGD patients who required renal replacement therapy (hemodialysis and transplant) and timeline to renal replacement therapy from CGD diagnosis. A second query on 02 May 2017 requested all antimicrobials (drug, indication, dose, outcome, complications) received by patients identified in the first query to have had a diagnosis...



We gratefully acknowledge The U.S. Immunodeficiency Network (USIDNET), a program of the Immune Deficiency Foundation (IDF), which is supported by a cooperative agreement, U24AI86837, from the National Institute of Allergy and Infectious Diseases (NIAID).

We acknowledge the enrolling physicians for the USIDNET:

Zuhair K Ballas

Kathryn M Edwards

Harry L Malech

Rebecca Marsh

Paul G Quie

Andrew H Urbach

Compliance with Ethical Standards

Conflict of Interest

The authors declared that they have no conflict of interest.


  1. 1.
    Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–69.CrossRefGoogle Scholar
  2. 2.
    Bolanowski A, Mannon RB, Holland SM, Malech HL, Aschan J, Palmblad J, et al. Successful renal transplantation in patients with chronic granulomatous disease. Am J Transplant. 2006;6(3):636–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Walther MM, Malech H, Berman A, Choyke P, Venzon DJ, Linehan WM, et al. The urological manifestations of chronic granulomatous disease. J Urol. 1992;147(5):1314–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Leiding JW, Marciano BE, Zerbe CS, DeRavin SS, Malech HL, Holland SM. Diabetes, renal and cardiovascular disease in p47 phox−/− chronic granulomatous disease. J Clin Immunol. 2013;33(4):725–30.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Siddiqui MR, Sanford T, Nair A, Zerbe CS, Hughes MS, Folio L, et al. Chronic Colovesical fistula leading to chronic urinary tract infection resulting in end-stage renal disease in a chronic granulomatous disease patient. Urol Case Rep. 2017;11:37–8.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hultqvist M, Olofsson P, Holmberg J, Backstrom BT, Tordsson J, Holmdahl R. Enhanced autoimmunity, arthritis, and encephalomyelitis in mice with a reduced oxidative burst due to a mutation in the Ncf1 gene. Proc Natl Acad Sci U S A. 2004;101(34):12646–51.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of MedicineMayo ClinicJacksonvilleUSA
  2. 2.Genetics and Molecular Biology Branch, National Human Genome Research InstituteNational Institutes of HealthBethesdaUSA
  3. 3.Division of Allergy and ImmunologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  4. 4.Department of Allergy and ImmunologyMayo ClinicRochesterUSA
  5. 5.Mayo Clinic Childrens Center, Division of Pediatric Allergy and ImmunologyMayo ClinicRochesterUSA

Personalised recommendations